Compare DexCom, Inc. (DXCM) vs LYFT Inc (LYFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs LYFT Inc — how do they compare? DexCom, Inc. trades at $77.28 (market cap $28.06B), while LYFT Inc trades at $15.92 (market cap $6.17B). The key difference: DexCom, Inc. is far larger — about 4.5× LYFT Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, LYFT Inc nearer its low. Which is the better fit depends on your goals.
| DXCM | LYFT | |
|---|---|---|
Market Cap | $28.06B | $6.17B |
Sector | Health | Industrials |
52-Week High | $89.53 | $24.57 |
52-Week Low | $54.84 | $12.65 |
Enterprise Value | $27.03B | $5.71B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
Lyft trades at $16.015, up 2.59% today, with a bullish technical signal and strong cash flow growth. The stock shows robust revenue expansion to $6.32B in 2025 and a net income surge to $2.84B, though recent EPS misses in Q1 2026 raise caution. Positive sentiment is driven by strategic hires and operational efficiency gains, while analyst consensus targets $17.86 with 37% buy ratings.
Lyft's outlook is supported by improving profitability and liquidity, but faces risks from competitive pricing pressures and autonomous vehicle integration challenges. The stock offers potential upside to consensus targets, yet investors must weigh execution risks against attractive valuation multiples like a P/E of 2.38.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About LYFT Inc
Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →
